The Global Human Enhancement Market is poised to grow strong during the forecast period 2017 to 2027.
Some of the prominent trends that the market is witnessing include rising inclination towards health and growth in smart sensors.
Report Highlights:
The report provides a detailed analysis on current and future market trends to identify the investment opportunities
Market forecasts till 2027, using estimated market values as the base numbers
Key market trends across the business segments, Regions and Countries
Key developments and strategies observed in the market
Market Dynamics such as Drivers, Restraints, Opportunities and other trends
In-depth company profiles of key players and upcoming prominent players
Growth prospects among the emerging nations through 2027
Market opportunities and recommendations for new investments.
Key Topics Covered:
1 Market Outline 1.1 Research Methodology 1.2 Market Trends 1.3 Regulatory Factors 1.4 Product Analysis 1.5 End User Analysis 1.6 Strategic Benchmarking 1.7 Opportunity Analysis
2 Executive Summary
3 Market Overview 3.1 Current Trends 3.1.1 Rising Inclination Towards Health 3.1.2 Growth in Smart Sensors 3.1.3 Recent Technological Developments in Human Enhancement 3.1.4 Growth Opportunities/Investment Opportunities 3.2 Drivers 3.3 Constraints 3.4 Industry Attractiveness
4 Human Enhancement Market, By Product 4.1 Wearable Enhancement 4.1.1 Wearable Enhancement Market Forecast to 2027 (US$ MN) 4.1.1.1 Wrist-wear 4.1.1.2 Body-wear 4.1.1.3 Eye-wear 4.1.1.4 Foot-wear 4.1.1.4 Other Wearable Enhancement 4.2 In-built Enhancement
5 Human Enhancement Market, By End-user 5.1 Healthcare 5.2 Defense 5.3 Medical 5.4 Industrial 5.5 Other End Users
6 Human Enhancement Market, By Geography
7 Key Player Activities 7.1 Mergers & Acquisitions 7.2 Partnerships, Joint Venture's, Collaborations and Agreements 7.3 Product Launch & Expansions 7.4 Other Activities
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
First Quarter 2024
Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.
The earnings release can be found at...
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...